Peer-influenced content. Sources you trust. No registration required. This is HCN.
The New England Journal of Medicine
AL amyloidosis presents a diagnostic challenge due to its varied symptoms, but advancements in therapeutic options, including CyBorD plus daratumumab and emerging antifibril monoclonal antibodies, offer hope for better patient management.
Cardiology July 9th 2024
In a recent study, 95% of ITP patients treated with the novel anti-CD38 monoclonal antibody, CM313, achieved two consecutive platelet counts of at least 50×10^9 per liter within just eight weeks, highlighting the therapy’s efficacy and rapid action.
Hematology July 1st 2024
Cancer Therapy Advisor
AI chatbots like ChatGPT-4 and Claude AI have demonstrated superior performance to oncologists in delivering accurate, empathetic, and readable responses to patient inquiries about cancer, suggesting a promising adjunct to clinical practice.
Hematology/Oncology June 24th 2024
HIT Consultant
Tempus AI, leveraging one of the world’s largest clinical and molecular oncology data libraries, files for an IPO, aiming to raise substantial funds to support its mission of advancing AI-powered precision medicine.
Teclistamab, a BCMA bispecific antibody, demonstrates a promising 63% overall response rate in heavily pretreated R/R MM patients, with manageable toxicity compared to CAR T-cell therapy.
Hematology/Oncology June 17th 2024
Clinical Advances in Hematology & Oncology
Pirtobrutinib offers a new line of therapy for CLL and SLL patients who have progressed after covalent BTK inhibitors and venetoclax, with a significant overall response rate and manageable adverse events.